Biotie Therapies - Company Announcement

Biotie to continue development of and maintain global rights to BTT-1023, its novel VAP-1 antibody for inflammatory disease

BIOTIE THERAPIES CORP.                 STOCK EXCHANGE RELEASE        22 APRIL,
2010  at 9.00 a.m.

Biotie to continue development of and maintain global rights to BTT-1023, its
novel VAP-1 antibody for inflammatory disease

Biotie announced today that it maintains global development and
commercialization rights to BTT-1023 (ex-Japan, Taiwan, Singapore, New Zealand,
and Australia), following Roche's decision not to exercise its opt-in right for
strategic portfolio reasons. BTT-1023 is Biotie's novel fully human monoclonal
antibody targeting vascular adhesion protein-1 (VAP-1) that has recently
completed a successful Phase Ib study in rheumatoid arthritis patients and is
due to complete a Phase Ib trial in psoriasis patients around mid-year 2010.

Timo Veromaa, Chief Executive Officer of Biotie, commented: "VAP-1 is a novel
target in inflammatory disease and BTT-1023 represents a truly exciting and
differentiated product for the treatment of rheumatoid arthritis, psoriasis and
other inflammatory conditions. Maintaining the rights to BTT-1023 in key
pharmaceutical markets enables us to initiate discussions with potential
partners and allows us to control how we maximize the value of this product. We
have a solid financial position and look forward to continuing the development
of BTT-1023 to its next value inflection point."

In January 2010, Biotie reported top-line data from a Phase Ib study
(BTT12-CD015) in rheumatoid arthritis patients. The study evaluated the safety,
tolerability and pharmacokinetics of repeated doses (up to 8mg/kg) of the
intravenously administered antibody in 24 rheumatoid arthritis patients with an
inadequate response to methotrexate. The trial showed that BTT-1023 was
generally well tolerated, and no serious or severe adverse events were reported.
Although not designed to enable statistical evaluation of therapeutic activity,
patients receiving the higher doses of BTT-1023 had better responses in several
standard assessments of treatment effect (including DAS28 and ACR scores)  than
those patients receiving placebo.

Turku, 22 April, 2010

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Investor relations manager
tel. +358 2 274 8911
e-mail:virve.nurmi@biotie.com <mailto:virve.nurmi@biotie.com>
www.biotie.com <http://www.biotie.com/>

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About BTT-1023 and VAP-1

BTT-1023 is a novel, fully human monoclonal antibody based on Medarex Inc.'s
HuMab technology. The product targets vascular adhesion protein-1 (VAP-1), an
endothelial adhesion molecule. Inhibiting VAP-1 reduces inflammation by
regulating the migration of leukocytes, or white blood cells, to inflamed
tissues. Pathological accumulation of white blood cells in tissue is a common
feature in many inflammatory diseases such as rheumatoid arthritis, ulcerative
colitis, and psoriasis. Biotie has licensed the rights to develop and
commercialize BTT-1023 in Japan, Taiwan, Singapore, New Zealand and Australia to
Seikagaku Corporation.

About Study BTT12-CD015

Study BTT12-CD015, conducted within the EU, was a randomized,
placebo-controlled, double-blind, multiple ascending dose study conducted in 4
sequential cohorts of 6 patients. Within each cohort, 5 patients were randomized
to receive active drug and 1 patient to receive placebo. The BTT-1023 doses in
the sequential cohorts were 1, 2, 4, and 8mg/kg. In this 4 month study, 5 doses
of study drug were administered intravenously at 2 week intervals with
post-treatment follow-up continuing for 9 weeks after the last dose.  Study
subjects were required to have active rheumatoid arthritis with a predefined
level of breakthrough symptoms while on a stable background regiment of
methotrexate. Safety and tolerability were assessed with adverse event inquiries
and comprehensive laboratory analyses, while treatment response was assessed
with a number of subjective and objective assessments that are widely used in
rheumatoid arthritis trials.

Biotie Therapies Corp.

Biotie is a drug discovery and development company focused on central nervous
system and inflammatory diseases. It has a broad range of innovative small
molecule and biological drug candidates at different stages of clinical and
pre-clinical development. Biotie's products address diseases with high unmet
medical need and significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary
disease (COPD). The most advanced product, nalmefene for alcohol dependence, is
currently in phase III clinical development by licensing partner H. Lundbeck
A/S.

The commercial value of the pipeline has been demonstrated through existing
alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche
and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Biotie shares are listed on NASDAQ OMX Helsinki Ltd.

For more information, please refer to www.biotie.com



[HUG#1406663]